Yangtze River's leading chemical drug brand TOP10!

According to the latest data from Mednet.
com on March 31, the chemical medicine market of public hospitals in key provinces and cities will be affected by the new crown epidemic in 2020, and sales have declined year-on-year.
From the perspective of TOP10 manufacturers, foreign-funded pharmaceutical companies occupy 7 seats, and there are only three domestic pharmaceutical companies: Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, and Yangzijiang Pharmaceutical Group.
Among the TOP10 products, anti-tumor and immunomodulators are the most, and 4 products have increased by more than 10% against the trend.
For the first time, PEGylated recombinant human granulocyte stimulating factor injection has ranked among the top five.
Among the TOP10 brands, Yangtze River’s Dezocine injection ranked first; AstraZeneca’s sales of Osimertinib mesylate tablets grew the fastest.
It is worth noting that although CP Tianqing Pharmaceutical Group's Anlotinib Hydrochloride Capsules ranks 17th, the growth rate is second only to AstraZeneca's Osimertinib Mesylate tablets, exceeding 40%.
In addition, due to the impact of biosimilar drugs in recent years, the market shares of Roche's "troika" trastuzumab, bevacizumab, and rituximab have all declined.

 

Anti-tumor and immunomodulators are selling well, Hengrui, Qilu, and Yangtze River "break through"

 

According to data from Meinenet, the chemical drug market in public hospitals in key provinces and cities has grown steadily in recent years.
In 2020, affected by the new crown epidemic, sales have declined year-on-year.
In terms of quarterly sales trends, in the first half of 2020, there will be a year-on-year decline of more than 15%, and a year-on-year decline of less than 3% in the second half of the year.
The market is gradually recovering.
From the perspective of broad categories, anti-tumor and immune modulators, digestive system and metabolic drugs, systemic anti-infective drugs, blood and hematopoietic system drugs, and nervous system drugs rank in the top five.

 

　　The chemical city structure of public hospitals in some key provinces and cities in 2020 (unit: 100 million yuan)

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　From the perspective of the urban structure, Guangdong ranks first in sales.
From the perspective of TOP10 manufacturers, foreign-funded pharmaceutical companies occupy 7 seats.
Domestic pharmaceutical companies are only Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, and Yangzijiang Pharmaceutical Group.
In terms of sales growth, Qilu Pharmaceutical is the fastest, exceeding 15% .

 

　　Yangtze River's leading brand TOP10, Chia Tai Tianqing, CSPC.
.
.
the rise of new domestic drugs

 

　　Top 10 chemical drug products in public hospitals in key provinces and cities in 2020

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　Among the TOP10 products, anti-tumor and immunomodulators are the most.
In addition, four major products, including PEGylated recombinant human granulocyte stimulating factor injection and tacrolimus capsules, grew by more than 10%.
Among them, PEGylated recombinant human granulocyte stimulating factor injection ranked among the top five for the first time.
Of the list.

 

　　Top 10 chemical drug brands in public hospitals in key provinces and cities in 2020

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　Among the TOP10 brands, Yangtze River's Dezocine injection ranked first; from the perspective of sales growth, AstraZeneca's Osimertinib mesylate tablets were the fastest, exceeding 60%.
It is worth noting that although CP Tianqing Pharmaceutical Group's Anlotinib Hydrochloride Capsules ranks 17th, its sales growth rate is second only to AstraZeneca's osimertinib mesylate tablets, exceeding 40%.
In addition, due to the impact of biosimilar drugs in recent years, the market shares of Roche's "troika" trastuzumab, bevacizumab, and rituximab have all declined.

 

　　Sales of pegylated recombinant human granulocyte stimulating factor injections in recent years

 

　　

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　PEGylated recombinant human granulocyte stimulating factor injection is an anti-tumor and immunomodulatory agent.
According to data from Menet.
com, the sales of PEGylated recombinant human granulocyte stimulating factor injections in public hospitals in key provinces and cities have increased rapidly in recent years, from less than 50 million yuan in 2015 to breaking through the 1.
5 billion mark in 2019, and hitting another mark in 2020.
new highs.
At present, the only companies producing PEGylated recombinant human granulocyte stimulating factor injection are CSPC (Shandong) Biopharmaceutical and Qilu Pharmaceutical, and the sales growth of the two companies will exceed 10% in 2020.
In addition, the listing application of PEGylated recombinant human granulocyte stimulating factor injection by Shandong New Times Pharmaceutical is under review and approval.

 

　　Sales of Butylphthalide Injections in Recent Years

 

　　

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　The trade name of butylphthalide is Enbipu, a national class 1 new drug, and it is an exclusive product with patent protection by CSPC.
According to data from Menet.
com, the sales of butylphthalide injections in public hospitals in key provinces and cities have increased rapidly in recent years, exceeding 1 billion yuan in 2020, an increase of more than 10% year-on-year.
CSPC stated in its 2020 annual report that both formulations of butylphthalide successfully passed the price negotiation of the National Medical Insurance Catalogue in December 2020.
The corresponding price reduction can greatly improve product availability, stimulate market demand, and promote Sales are growing rapidly.
Although the price drop will bring certain pressure on the sales of the product in the short term, it may speed up the access of the product to hospitals and resolve the risk of being included in the centralized procurement catalogue of the country and various provinces and cities.
The group will continue to do a good job The sinking of the market has increased the coverage of drug users and benefited more patients.
In terms of research and development, while butylphthalide continues to strengthen clinical evidence, it is also actively exploring new therapeutic areas.
There are currently 155 research projects in progress.
Among them, the overall clinical trials of butylphthalide soft capsules in the treatment of vascular dementia are progressing smoothly.
Enrollment is in progress.
The phase II clinical trial of butylphthalide soft capsules in the United States has ended early due to the epidemic, and case enrollment is in progress.
Data analysis is ongoing.
New indications and new market development will bring new growth after the expiration of the butylphthalide patent.
opportunity.

 

　　Sales of Anlotinib Capsules in Recent Years

 

　　

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　Anlotinib Hydrochloride Capsules is a new class 1 anti-tumor drug developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceuticals.
According to data from Minai.
com, the sales of Anlotinib capsules in public hospitals in key provinces and cities have increased rapidly in recent years.
In 2019, the sales surged by more than 1500%, and the sales in 2020 exceeded 900 million yuan.
A few days ago, China Biopharmaceuticals issued a 2020 performance announcement.
The anti-tumor product Anlotinib has been approved for the three major indications of non-small cell lung cancer, small cell lung cancer, and soft tissue sarcoma and all entered the national medical insurance catalog.
23 products, a strong product portfolio covering multiple solid tumors and hematoma indications, many new products, strong revenue growth, accounting for one-third of the total revenue, and becoming the most important product area of ​​the group.
In February this year, Anlotinib was approved for the fourth indication for the treatment of medullary thyroid cancer.
China Biopharmaceuticals stated that as the first small-molecule multi-target receptor tyrosine kinase inhibitor approved for the treatment of medullary thyroid cancer in China, Anlotinib broke the deadlock of drug-free medullary thyroid cancer.
Clinicians provide treatment options to benefit patients with medullary thyroid cancer.

 

　　Sales of trastuzumab/bevacizumab/rituximab injections in recent years

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　In February of this year, Roche disclosed its 2020 performance.
Among them, the sales of trastuzumab, bevacizumab, and rituximab, which are known as Roche's "troika", have fallen sharply.
According to data from Minai.
com, in 2020, Roche's bevacizumab injection, trastuzumab for injection, and rituximab injection from public hospitals in key provinces and cities are among the TOP10 brands, but their sales have increased significantly.
Among them, bevacizumab injection and trastuzumab for injection both fell by more than 15% year-on-year; rituximab injection fell by more than 20% year-on-year.
In recent years, with the efforts of domestic pharmaceutical companies, Roche's "troika" dominance has gradually been broken.
Up to now, there are three manufacturers of bevacizumab injection: Roche, Qilu Pharmaceutical, and Xinda Bio; Trastuzumab for injection has Roche and Fuhong Hanlin; and Rituximab injection has Roche, Fuhong Henlius and Xinda Biological.

 

　　Recently, Henlius Group announced its 2020 results.
Among them, rituximab (trade name Hanlikang) is China’s first biosimilar drug, and its domestic commercial sales are handled by Jiangsu Fosun, a subsidiary of Fosun Pharma .
In 2020, about 720,000 pieces of this product will be shipped.
The company will realize sales revenue of 288 million yuan based on the profit sharing with Jiangsu Fosun, and realize license revenue of about 10.
4 million yuan, which represents a substantial increase in revenue.
As of the end of 2020, Han Likang has completed the opening of medical insurance in 30 provinces and cities across the country, of which 28 provinces and cities have completed the official online/recorded procurement, and realized the purchase of medicines in nearly 70% of the core hospitals.
In 2020, Hanlikang completed the expansion of the production scale of 2000 liters, added 500mg/50ml/bottle product specifications, etc.
, and successfully extrapolated two new indications, and commercialization was accelerated in an all-round way.
In addition, trastuzumab (trade name Hanquyou) will have a sales revenue of 136 million yuan in Central Europe in 2020.
Up to now, medical insurance access has been opened in all provinces and cities across the country, and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding has been completed in 28 provinces and cities .
In 2021, we will further expand the sales team of the product and strengthen the sales network plan, actively launch cooperation, and accelerate the product's market sinking.
The supplementary application (sNDA) for the new 60mg/bottle of Hanquyou has been accepted by the State Food and Drug Administration, and it is expected to be approved for listing in the third quarter of this year.

 

　　Source: Mi Nei.
com database, public company announcements

 

　　Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities is based on the chemical drug pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities, and the sample provincial and municipal sample hospitals that continuously monitor the entire category of chemical drugs database.
The data covers 14 categories, 90 subcategories, and a total of 4800+ generic name varieties, which can analyze the drug use structure of medical institutions from multiple angles and dimensions.
This data is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of chemical drugs in 20+ provinces and cities in all categories in an all-round and multi-dimensional manner.

　　According to the latest data from Mednet.
com on March 31, the chemical medicine market of public hospitals in key provinces and cities will be affected by the new crown epidemic in 2020, and sales have declined year-on-year.
From the perspective of TOP10 manufacturers, foreign-funded pharmaceutical companies occupy 7 seats, and there are only three domestic pharmaceutical companies: Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, and Yangzijiang Pharmaceutical Group.
Among the TOP10 products, anti-tumor and immunomodulators are the most, and 4 products have increased by more than 10% against the trend.
For the first time, PEGylated recombinant human granulocyte stimulating factor injection has ranked among the top five.
Among the TOP10 brands, Yangtze River’s Dezocine injection ranked first; AstraZeneca’s sales of Osimertinib mesylate tablets grew the fastest.
It is worth noting that although CP Tianqing Pharmaceutical Group's Anlotinib Hydrochloride Capsules ranks 17th, the growth rate is second only to AstraZeneca's Osimertinib Mesylate tablets, exceeding 40%.
In addition, due to the impact of biosimilar drugs in recent years, the market shares of Roche's "troika" trastuzumab, bevacizumab, and rituximab have all declined.

 

　　Anti-tumor and immunomodulators are selling well, Hengrui, Qilu, and Yangtze River "break through"

 

　　According to data from Meinenet, the chemical drug market in public hospitals in key provinces and cities has grown steadily in recent years.
In 2020, affected by the new crown epidemic, sales have declined year-on-year.
In terms of quarterly sales trends, in the first half of 2020, there will be a year-on-year decline of more than 15%, and a year-on-year decline of less than 3% in the second half of the year.
The market is gradually recovering.
From the perspective of broad categories, anti-tumor and immune modulators, digestive system and metabolic drugs, systemic anti-infective drugs, blood and hematopoietic system drugs, and nervous system drugs rank in the top five.

 

　　The chemical city structure of public hospitals in some key provinces and cities in 2020 (unit: 100 million yuan)

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　From the perspective of the urban structure, Guangdong ranks first in sales.
From the perspective of TOP10 manufacturers, foreign-funded pharmaceutical companies occupy 7 seats.
Domestic pharmaceutical companies are only Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, and Yangzijiang Pharmaceutical Group.
In terms of sales growth, Qilu Pharmaceutical is the fastest, exceeding 15% .

 

　　Yangtze River's leading brand TOP10, Chia Tai Tianqing, CSPC.
.
.
the rise of new domestic drugs

 

　　Top 10 chemical drug products in public hospitals in key provinces and cities in 2020

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　Among the TOP10 products, anti-tumor and immunomodulators are the most.
In addition, four major products, including PEGylated recombinant human granulocyte stimulating factor injection and tacrolimus capsules, grew by more than 10%.
Among them, PEGylated recombinant human granulocyte stimulating factor injection ranked among the top five for the first time.
Of the list.

 

　　Top 10 chemical drug brands in public hospitals in key provinces and cities in 2020

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　Among the TOP10 brands, Yangtze River's Dezocine injection ranked first; from the perspective of sales growth, AstraZeneca's Osimertinib mesylate tablets were the fastest, exceeding 60%.
It is worth noting that although CP Tianqing Pharmaceutical Group's Anlotinib Hydrochloride Capsules ranks 17th, its sales growth rate is second only to AstraZeneca's osimertinib mesylate tablets, exceeding 40%.
In addition, due to the impact of biosimilar drugs in recent years, the market shares of Roche's "troika" trastuzumab, bevacizumab, and rituximab have all declined.

 

　　Sales of pegylated recombinant human granulocyte stimulating factor injections in recent years

 

　　

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　PEGylated recombinant human granulocyte stimulating factor injection is an anti-tumor and immunomodulatory agent.
According to data from Menet.
com, the sales of PEGylated recombinant human granulocyte stimulating factor injections in public hospitals in key provinces and cities have increased rapidly in recent years, from less than 50 million yuan in 2015 to breaking through the 1.
5 billion mark in 2019, and hitting another mark in 2020.
new highs.
At present, the only companies producing PEGylated recombinant human granulocyte stimulating factor injection are CSPC (Shandong) Biopharmaceutical and Qilu Pharmaceutical, and the sales growth of the two companies will exceed 10% in 2020.
In addition, the listing application of PEGylated recombinant human granulocyte stimulating factor injection by Shandong New Times Pharmaceutical is under review and approval.

 

　　Sales of Butylphthalide Injections in Recent Years

 

　　

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　The trade name of butylphthalide is Enbipu, a national class 1 new drug, and it is an exclusive product with patent protection by CSPC.
According to data from Menet.
com, the sales of butylphthalide injections in public hospitals in key provinces and cities have increased rapidly in recent years, exceeding 1 billion yuan in 2020, an increase of more than 10% year-on-year.
CSPC stated in its 2020 annual report that both formulations of butylphthalide successfully passed the price negotiation of the National Medical Insurance Catalogue in December 2020.
The corresponding price reduction can greatly improve product availability, stimulate market demand, and promote Sales are growing rapidly.
Although the price drop will bring certain pressure on the sales of the product in the short term, it may speed up the access of the product to hospitals and resolve the risk of being included in the centralized procurement catalogue of the country and various provinces and cities.
The group will continue to do a good job The sinking of the market has increased the coverage of drug users and benefited more patients.
In terms of research and development, while butylphthalide continues to strengthen clinical evidence, it is also actively exploring new therapeutic areas.
There are currently 155 research projects in progress.
Among them, the overall clinical trials of butylphthalide soft capsules in the treatment of vascular dementia are progressing smoothly.
Enrollment is in progress.
The phase II clinical trial of butylphthalide soft capsules in the United States has ended early due to the epidemic, and case enrollment is in progress.
Data analysis is ongoing.
New indications and new market development will bring new growth after the expiration of the butylphthalide patent.
opportunity.

 

　　Sales of Anlotinib Capsules in Recent Years

 

　　

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　Anlotinib Hydrochloride Capsules is a new class 1 anti-tumor drug developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceuticals.
According to data from Minai.
com, the sales of Anlotinib capsules in public hospitals in key provinces and cities have increased rapidly in recent years.
In 2019, the sales surged by more than 1500%, and the sales in 2020 exceeded 900 million yuan.
A few days ago, China Biopharmaceuticals issued a 2020 performance announcement.
The anti-tumor product Anlotinib has been approved for the three major indications of non-small cell lung cancer, small cell lung cancer, and soft tissue sarcoma and all entered the national medical insurance catalog.
23 products, a strong product portfolio covering multiple solid tumors and hematoma indications, many new products, strong revenue growth, accounting for one-third of the total revenue, and becoming the most important product area of ​​the group.
In February this year, Anlotinib was approved for the fourth indication for the treatment of medullary thyroid cancer.
China Biopharmaceuticals stated that as the first small-molecule multi-target receptor tyrosine kinase inhibitor approved for the treatment of medullary thyroid cancer in China, Anlotinib broke the deadlock of drug-free medullary thyroid cancer.
Clinicians provide treatment options to benefit patients with medullary thyroid cancer.

 

　　Sales of trastuzumab/bevacizumab/rituximab injections in recent years

　　Source: Competitive pattern of chemical medicine terminal in public hospitals of key provinces and cities

 

　　In February of this year, Roche disclosed its 2020 performance.
Among them, the sales of trastuzumab, bevacizumab, and rituximab, which are known as Roche's "troika", have fallen sharply.
According to data from Minai.
com, in 2020, Roche's bevacizumab injection, trastuzumab for injection, and rituximab injection from public hospitals in key provinces and cities are among the TOP10 brands, but their sales have increased significantly.
Among them, bevacizumab injection and trastuzumab for injection both fell by more than 15% year-on-year; rituximab injection fell by more than 20% year-on-year.
In recent years, with the efforts of domestic pharmaceutical companies, Roche's "troika" dominance has gradually been broken.
Up to now, there are three manufacturers of bevacizumab injection: Roche, Qilu Pharmaceutical, and Xinda Bio; Trastuzumab for injection has Roche and Fuhong Hanlin; and Rituximab injection has Roche, Fuhong Henlius and Xinda Biological.

 

　　Recently, Henlius Group announced its 2020 results.
Among them, rituximab (trade name Hanlikang) is China’s first biosimilar drug, and its domestic commercial sales are handled by Jiangsu Fosun, a subsidiary of Fosun Pharma .
In 2020, about 720,000 pieces of this product will be shipped.
The company will realize sales revenue of 288 million yuan based on the profit sharing with Jiangsu Fosun, and realize license revenue of about 10.
4 million yuan, which represents a substantial increase in revenue.
As of the end of 2020, Han Likang has completed the opening of medical insurance in 30 provinces and cities across the country, of which 28 provinces and cities have completed the official online/recorded procurement, and realized the purchase of medicines in nearly 70% of the core hospitals.
In 2020, Hanlikang completed the expansion of the production scale of 2000 liters, added 500mg/50ml/bottle product specifications, etc.
, and successfully extrapolated two new indications, and commercialization was accelerated in an all-round way.
In addition, trastuzumab (trade name Hanquyou) will have a sales revenue of 136 million yuan in Central Europe in 2020.
Up to now, medical insurance access has been opened in all provinces and cities across the country, and pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding has been completed in 28 provinces and cities .
In 2021, we will further expand the sales team of the product and strengthen the sales network plan, actively launch cooperation, and accelerate the product's market sinking.
The supplementary application (sNDA) for the new 60mg/bottle of Hanquyou has been accepted by the State Food and Drug Administration, and it is expected to be approved for listing in the third quarter of this year.

 

　　Source: Mi Nei.
com database, public company announcements

 

　　Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities is based on the chemical drug pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities, and the sample provincial and municipal sample hospitals that continuously monitor the entire category of chemical drugs database.
The data covers 14 categories, 90 subcategories, and a total of 4800+ generic name varieties, which can analyze the drug use structure of medical institutions from multiple angles and dimensions.
This data is updated quarterly to provide timely feedback on the impact of policy changes on products, and analyze the sales, market shares, sales trends and development laws of various categories and varieties of chemical drugs in 20+ provinces and cities in all categories in an all-round and multi-dimensional manner.